Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beta Bionics, Inc. - Common Stock (NQ:BBNX)

15.81 -0.18 (-1.13%)
Streaming Delayed Price Updated: 10:44 AM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beta Bionics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
From Johnson Fistel, PLLP
Via Business Wire
News headline image
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
From Johnson Fistel, PLLP
Via Business Wire
News headline image
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
New dashboard at betabionics.com shows every patient, every baseline, every outcome, with no filters and no fine print 
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics Inc (NASDAQ:BBNX) Beats Q1 2026 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
Beta Bionics Inc (NASDAQ:BBNX) Reports Q4 Earnings Beat and Provides 2026 Revenue Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
From Robbins LLP
Via Business Wire
News headline image
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans ↗
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales... 
Via MarketBeat
News headline image
Beta Bionics to Present at the Bank of America Securities Health Care Conference
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics BBNX Q1 2026 Earnings Transcript ↗
Beta Bionics BBNX Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic Pancreas 
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ONGOING INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Beta Bionics (NASDAQ: BBNX)
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
BBNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Beta Bionics (BBNX) Q4 2025 Earnings Transcript ↗
Beta Bionics (BBNX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
BBNX SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.